The Tranzyme drug, TZP-102, failed to significantly reduce the symptoms of gastroparesis compared to a placebo, according to results from a phase IIb study.
Tranzyme shares closed Wednesday at $3.97.
Gastroparesis is a progressive disorder that causes the stomach to become paralyzed, leading to nausea, vomiting and digestion problems. In diabetic patients, gastroparesis can make it harder to take diabetes medicines, which keeps blood glucose levels under control. There are no currently approved drugs to treat gastroparesis. TZP-102 is designed to stimulate stomach movement.Tranzyme's phase IIb study compared two doses of TZP-102 taken once daily against a placebo. After 12 weeks of treatment, all patients saw a reduction in gastroparesis symptoms but the difference between TZP-102 and placebo was small and not statistically significant. A second phase II study of TZP-102 is underway which doses the drug three times daily. Results are expected in the first half of 2013, Tranzyme said. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV